ChemSpider 2D Image | Alvocidib hydrochloride | C21H21Cl2NO5

Alvocidib hydrochloride

  • Molecular FormulaC21H21Cl2NO5
  • Average mass438.301 Da
  • Monoisotopic mass437.079681 Da
  • ChemSpider ID8086637
  • defined stereocentres - 2 of 2 defined stereocentres


More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methyl-4-piperidinyl]-4h-1-benzopyran-4-one hydrochloride
131740-09-5 [RN]
2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-chromen-4-one hydrochloride (1:1) [ACD/IUPAC Name]
2-(2-Chlorophényl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-méthyl-4-pipéridinyl]-4H-chromén-4-one, chlorhydrate (1:1) [French] [ACD/IUPAC Name]
2-(2-Chlorphenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-chromen-4-onhydrochlorid (1:1) [German] [ACD/IUPAC Name]
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-, hydrochloride (1:1) [ACD/Index Name]
Alvocidib hydrochloride [USAN]
D48MS3A6N9
Flavopiridol (Hydrochloride)
Flavopiridol Hydrochloride
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

NSC-649890 [DBID]
D02880 [DBID]
F3055_SIGMA [DBID]
HL 275 [DBID]
HL-275 [DBID]
HMR 1275 [DBID]
HMR-1275 [DBID]
L 86 8275 [DBID]
L86-8275 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Chemical Class:

      A hydrochloride salt resulting from the formal reaction of equimolar amounts of alvocidib and hydrogen chloride. A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. ChEBI CHEBI:90998, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90998
    • Bio Activity:

      CDK MedChem Express HY-10006
      Cell Cycle/DNA Damage MedChem Express HY-10006
      Cell Cycle/DNA Damage; MedChem Express HY-10006
      Cyclin-dependent Kinase Tocris Bioscience 3094
      Cyclin-dependent kinase (CDK) inhibitor that causes cell cycle arrest at G1 and G2 phase. Potently inhibits the growth of breast and lung cancer cell lines (IC50 = 25 - 160 nM) in vitro. Tocris Bioscience 3094
      Cyclin-dependent kinase inhibitor Tocris Bioscience 3094
      Enzymes Tocris Bioscience 3094
      Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. MedChem Express HY-10006
      Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA.;IC50 Value: ~ 40 nM;Target: CDK;In vitro: Flavopiridol induces G1 arrest with inhibition of CDK2 and CDK4 in human breast carcinoma cells in a time and concentration dependent manner. Short time treatment of Flavopiridol (~12 hours) induce apoptosis in hematopoietic cell lines including SUDHL4, SUDHL6 (B-cell lines), Jurkat and MOLT4 (T-cell lines ), and HL60 (myeloid). In the clonogenic assay, Flavopiridol functions as a highly potent cytotoxic compound with a mean IC70 with 8 ng/mL in 23 human tumor models. A recent study shows Flavopiridol treatment induces a substantial AKT-Ser473 phosphorylation in human glioblastoma T98G cell line.;In vivo: After treatment with 7.5 mg/kg Flavopiridol bolus intravenous (IV) or intraperitoneal on each of 5 consecuti MedChem Express HY-10006
      Kinases Tocris Bioscience 3094

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site






Advertisement